Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs.

[1]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[2]  C. Serhan,et al.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.

[3]  Marc Parmentier,et al.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family , 2009, Pharmacological Reviews.

[4]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[5]  Yan Lu,et al.  Resolvin E1 Metabolome in Local Inactivation during Inflammation-Resolution1 , 2008, The Journal of Immunology.

[6]  C. Serhan,et al.  Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. , 2008, Bioorganic & medicinal chemistry letters.

[7]  M. Perretti,et al.  Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. , 2007, Journal of medicinal chemistry.

[8]  Charles N. Serhan,et al.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.

[9]  C. Serhan.  Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[10]  R. Eglen,et al.  Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. , 2007, Assay and drug development technologies.

[11]  Takao Shimizu,et al.  The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo , 2006, Pharmacological Reviews.

[12]  John Savill,et al.  Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.

[13]  Charles N. Serhan,et al.  Molecular circuits of resolution: formation and actions of resolvins and protectins , 2005, The Journal of Immunology.

[14]  B. Weichman.  Inflammation: basic principles and clinical correlates , 1988, Agents and Actions.

[15]  Shubhada Sankararaman,et al.  Cells, Tissues, and Disease: Principles of General Pathology , 2005 .

[16]  J. Parkinson,et al.  A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Serhan,et al.  Lipoxins and novel 15‐epi‐lipoxin analogs display potent anti‐inflammatory actions after oral administration , 2004, British journal of pharmacology.

[18]  Adriano G. Rossi,et al.  Inflammatory Resolution: new opportunities for drug discovery , 2004, Nature Reviews Drug Discovery.

[19]  J. Uddin,et al.  Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway , 2004, Nature Immunology.

[20]  A. Schottelius,et al.  Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. , 2004, Journal of medicinal chemistry.

[21]  C. Godson,et al.  Lipoxins: endogenous regulators of inflammation. , 2004, American journal of physiology. Renal physiology.

[22]  C. Clish,et al.  Lipoxin A4 and Aspirin-Triggered 15-epi-Lipoxin A4 Inhibit Human Neutrophil Migration: Comparisons Between Synthetic 15 Epimers in Chemotaxis and Transmigration with Microvessel Endothelial Cells and Epithelial Cells 1 , 2003, The Journal of Immunology.

[23]  Carl Nathan,et al.  Points of control in inflammation , 2002, Nature.

[24]  K. Asadullah,et al.  An Aspirin-Triggered Lipoxin A4 Stable Analog Displays a Unique Topical Anti-Inflammatory Profile , 2002, The Journal of Immunology.

[25]  J. Wallace,et al.  Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. , 2002, Gastroenterology.

[26]  Eugene Y. Kim,et al.  Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4 , 2002, Nature Medicine.

[27]  B. Levy,et al.  Oxidoreductases in Lipoxin A4 Metabolic Inactivation , 2000, The Journal of Biological Chemistry.

[28]  C. Serhan,et al.  Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking1 , 2000, The Journal of Immunology.

[29]  Hugh R. Brady,et al.  Cutting Edge: Lipoxins Rapidly Stimulate Nonphlogistic Phagocytosis of Apoptotic Neutrophils by Monocyte-Derived Macrophages1 , 2000, The Journal of Immunology.

[30]  C. Clish,et al.  Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Freeman,et al.  Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. , 1999, The Journal of clinical investigation.

[32]  C. Serhan,et al.  Lipoxin (LX)A4 and Aspirin-triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor 1α–initiated Neutrophil Responses and Trafficking: Regulators of a Cytokine–Chemokine Axis , 1999, The Journal of experimental medicine.

[33]  Andrea Messori,et al.  New drugs for rheumatoid arthritis [6] (multiple letters) , 2004 .

[34]  S. Kurozumi,et al.  Palladium-catalyzed coupling reactions of bromobenzaldehydes with 3,4-di(tert-butyldimethylsilyloxy)-1-alkene to (3,4-dihydroxyalkenyl)benzaldehydes in the synthesis of lipoxin analogues , 1998 .

[35]  T. Takano,et al.  Lipoxin A4 Stable Analogs Are Potent Mimetics That Stimulate Human Monocytes and THP-1 Cells via a G-protein-linked Lipoxin A4 Receptor* , 1997, The Journal of Biological Chemistry.

[36]  C. Serhan,et al.  Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction , 1996, The Journal of experimental medicine.

[37]  G. Majno,et al.  Cells, tissues, and disease : principles of general pathology , 1996 .

[38]  I. Akritopoulou‐Zanze,et al.  Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. , 1995, Biochemistry.

[39]  S. Gelman.  The Pathophysiology of Aortic Cross-clamping and Unclamping , 1995, Anesthesiology.

[40]  John I. Gallin,et al.  Inflammation: Basic Principles and Clinical Correlates , 1992 .